(Albany, USA) DelveInsight’s “Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Alzheimer’s Disease, historical and forecasted epidemiology as well as the Alzheimer’s Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Alzheimer’s Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Alzheimer’s Disease market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Alzheimer’s Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Alzheimer’s Disease market.

 

Request for a Free Sample Report @ Alzheimer’s Disease Market Forecast

 

Some facts of the Alzheimer’s Disease Market Report are:

• According to DelveInsight, Alzheimer’s Disease market size is expected to grow at a decent CAGR by 2032.
• Leading Alzheimer’s Disease companies working in the market are Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., Stemedica Cell Technologies, Inc. and many others.
• As per Alzheimer’s Disease pipeline analysis, there are currently 150+ companies and 150+ pipeline drugs depicting a pretty fertile picture of the market in the cooking years.
• Key Alzheimer’s Disease Therapies expected to launch in the market are Lecanemab (BAN2401), Tricaprilin, Aducanumab (BIIB037), Gantenerumab (RG1450, RO4909832), Brexpiprazole (REXULTI / RXULTI), AL002, ALZT-OP1, Brilaroxazine (RP5063), BIIB076, and others.
• In 2023, the U.S. Food and Drug Administration (FDA) approved lecanemab (Leqembi) for people with mild Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s disease. A phase 3 clinical trial found that the medicine slowed cognitive decline in people with early Alzheimer’s disease.
• Aducanumab was the first therapy to demonstrate that removing beta-amyloid, one of the hallmarks of Alzheimer’s disease, from the brain reduces cognitive and functional decline in people living with early Alzheimer’s.
• In 2023, Eli Lilly announced it had met the primary endpoint in a Phase III study of donanemab, having slowed clinical decline in patients with mild to moderate Alzheimer’s disease (AD) by 35% compared to placebo. As against previously approved anti-amyloid therapies like lecanemab marketed as Leqembi, and Biogen’s aducanumab marketed as Aduhelm, donanemab showed higher levels of efficacy indicating another success for those researching Alzheimer’s disease.

 

Alzheimer’s disease Overview

Alzheimer’s disease is a progressive neurological disorder characterized by memory loss, cognitive decline, and changes in behaviour. It is the most common form of dementia, affecting millions of people worldwide. The disease gradually damages brain cells, leading to the impairment of memory, thinking, and communication skills. As the condition progresses, individuals may struggle with daily tasks and experience personality changes. There is currently no cure for Alzheimer’s disease, but various treatments and therapies can help manage symptoms and improve quality of life. Ongoing research aims to better understand the disease’s causes and develop more effective interventions.

 

Learn more about Alzheimer’s Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market

 

Alzheimer’s Disease Market 

The Alzheimer’s Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Alzheimer’s Disease market trends by analyzing the impact of current Alzheimer’s Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Alzheimer’s Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alzheimer’s Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Alzheimer’s Disease market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Alzheimer’s Disease Epidemiology 

The Alzheimer’s Disease epidemiology section provides insights into the historical and current Alzheimer’s Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Alzheimer’s Disease market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Alzheimer’s Disease Epidemiology @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market

 

Alzheimer’s Disease Drugs Uptake

This section focuses on the uptake rate of the potential Alzheimer’s Disease drugs recently launched in the Alzheimer’s Disease market or expected to be launched in 2019-2032. The analysis covers the Alzheimer’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Alzheimer’s Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Alzheimer’s Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Alzheimer’s Disease Pipeline Development Activities

The Alzheimer’s Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Alzheimer’s Disease key players involved in developing targeted therapeutics.

• Lecanemab (BAN2401): Eisai/ BioArctic AB (Sweden)
• Tricaprilin: Cerecin
• Aducanumab (BIIB037): Biogen
• Gantenerumab (RG1450, RO4909832): Chugai Pharmaceuticals (Hoffmann-La Roche)
• Brexpiprazole (REXULTI / RXULTI): Otsuka Pharmaceutical
• AL002: Alector
• ALZT-OP1: AZ Therapies
• Brilaroxazine (RP5063): Reviva Pharmaceuticals
• BIIB076: Neurimmune

 

Request for a sample report to understand more about the Alzheimer’s Disease pipeline development activities @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market

 

Alzheimer’s Disease Therapeutics Assessment

Major key companies are working proactively in the Alzheimer’s Disease Therapeutics market to develop novel therapies which will drive the Alzheimer’s Disease treatment markets in the upcoming years are Eisai/ BioArctic AB, Biogen, Otsuka Pharmaceutical, Hoffmann-La Roche/Chugai Pharmaceuticals, Alector, AbbVie, Reviva Pharmaceutical, AZ Therapies, Cerecin, Anavex Life Sciences Corp., Neurimmune, and others.

 

Learn more about the emerging Alzheimer’s Disease therapies & key companies @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market

 

Alzheimer’s Disease Report Key Insights

1. Alzheimer’s Disease Patient Population

2. Alzheimer’s Disease Market Size and Trends

3. Key Cross Competition in the Alzheimer’s Disease Market

4. Alzheimer’s Disease Market Dynamics (Key Drivers and Barriers)

5. Alzheimer’s Disease Market Opportunities

6. Alzheimer’s Disease Therapeutic Approaches

7. Alzheimer’s Disease Pipeline Analysis

8. Alzheimer’s Disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Alzheimer’s Disease Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Alzheimer’s Disease Competitive Intelligence Analysis

4. Alzheimer’s Disease Market Overview at a Glance

5. Alzheimer’s Disease Disease Background and Overview

6. Alzheimer’s Disease Patient Journey

7. Alzheimer’s Disease Epidemiology and Patient Population

8. Alzheimer’s Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Alzheimer’s Disease Unmet Needs

10. Key Endpoints of Alzheimer’s Disease Treatment

11. Alzheimer’s Disease Marketed Products

12. Alzheimer’s Disease Emerging Therapies

13. Alzheimer’s Disease Seven Major Market Analysis

14. Attribute Analysis

15. Alzheimer’s Disease Market Outlook (7 major markets)

16. Alzheimer’s Disease Access and Reimbursement Overview

17. KOL Views on the Alzheimer’s Disease Market

18. Alzheimer’s Disease Market Drivers

19. Alzheimer’s Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services